Visceral Leishmaniasis after Anti-Interleukin 17A (IL-17A) Therapy in a Patient Affected by Psoriatic Arthritis

Lupia, Tommaso; Corcione, Silvia; Fornari, Valentina; Rizzello, Barbara; Bosio, Roberta; Brusa, Maria Teresa; Rosa, Francesco Giuseppe De

doi:10.3390/tropicalmed7100319

Cited by 4 publications

(2 citation statements)

References 20 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, IL-17, in combination with IL-22 ( 44 ) or alone ( 45 ), has been demonstrated to have a role in protection and resistance against VL. However, other studies have associated IL-17 to VL susceptibility via the regulation of the IFN-γ response ( 46 , 47 ).…”

Section: Discussionmentioning

confidence: 99%

CD4+ Th1 and Th17 responses and multifunctional CD8 T lymphocytes associated with cure or disease worsening in human visceral leishmaniasis

de Franca,

Rodrigues,

Barreto

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

IntroductionIn VL, a proinflammatory phenotype is typically associated with enhanced phagocytosis and a Th1 mediated immune response resulting in infection control. In contrast, an anti-inflammatory phenotype, associated with a predominant regulatory response, typically enables intracellular multiplication of Leishmania parasites and disease progression.MethodsTo investigate the impact of chemotherapy on Th2 and Th17 immune responses in patients with visceral leishmaniasis (VL), we assessed all combinations of intracellular expression of IFN-γ, IL-10, IL-4 and IL-17 in the CD4+ and CD8+ T cell populations of peripheral blood mononuclear cell (PBMC) samples from patients, after antigenic stimulation with Leishmania lysate, throughout treatment and follow-up. As increases in spleen and liver sizes and decreases in hematocrit, hemogloblin, erythrocytes, monocytes, leukocytes and platelets levels are strongly related to the disease, we studied the correlations between the frequencies of T cells producing the afore mentioned cytokines, individually and in combination, and these variables, as markers of disease or cure.ResultsWe found that the frequency of IFN-γ-producingCD4+ T cells increased until the end of chemotherapy with Glucantime® or AmBisome ®, while IL-10, IL-4 and IL-17-producing CD4+ T cells peaked on day 7 following the start of treatment. Although the frequency of CD4+IL-17+ cells decreased during treatment an increase was observed after clinical cure. The frequency of CD4+ T cells producing only IFN-γ or IL-17 correlated with blood monocytes levels. Frequencies of double-producers of IFN-γ and IL-10 or IL-4 correlated positively with eosinophils and platelets levels. Together, this suggest that IFN-γ drives the immune response towards Th1 at cure. In contrast, and associated with disease or Th2 response, the frequency of CD4+ IL-10+ cells correlated positively with spleen sizes and negatively with circulating monocyte levels, while the frequency of CD4+ producing both IL-4 and IL-10 correlated negatively with platelets levels. The frequency of CD8+ single-producers of IFN-γ increased from day 21 to 90 while that of single-producers of IL-10 peaked on day 7, of IL-4 on day 30 and of IL-17, on day 180. IFN-γ expression in CD8+ single- and double-producers of cytokines was indicative of an immune response associated with cure. In contrast, frequencies of CD8+ double-producers of IL-4 and IL-10, IL-4 and IL-17 and IL-10 and IL-17 and producers of three and four cytokines, were associated with disease and were low after the cure. Frequencies of CD8+ T cells producing IFN-γ alone or with IL-17 were positively correlated with platelets levels. In contrast, as markers of disease: 1) frequencies of single producers of IL-10 correlated negatively with leukocytes levels, 2) frequencies of double producers of IL-4 and IL-10 correlated negatively with platelet, leukocyte, lymphocyte and circulating monocyte levels, 3) frequencies of triple-producers of IFN-γ, IL-4 and IL-10 correlated negatively with platelet, leukocyte and neutrophil levels and 4) frequencies of producers of IFN-γ, IL-4, IL-10 and IL-17 simultaneously correlated positively with spleen size, and negatively with leukocyte and neutrophil levels.DiscussionOur results confirmed that the clinical improvement of VL patients correlates with the decrease of an IL-4 and IL-10 CD4+Th2 response, the recovery of CD4+ Th1 and Th17 responses and the frequency of CD8+ single-producers of IFN-γ and double producers of IFN-γ and IL-17.

show abstract

Section: Discussionmentioning

confidence: 99%

CD4+ Th1 and Th17 responses and multifunctional CD8 T lymphocytes associated with cure or disease worsening in human visceral leishmaniasis

de Franca,

Rodrigues,

Barreto

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Only 1 case of leishmaniasis has been reported in a male patient with psoriatic arthritis who was under treatment with anti-IL-17 (secukinumab [SEC]), but he continued with this same drug after the resolution of the infection. 4 Thus, based on the pathways of L. donovani promastigotes infection and the literature review, we considered SEC (an inhibitor of IL-17) as a potential treatment in this patient.…”

Section: To the Editormentioning

confidence: 99%

Safe Treatment With Secukinumab in a Patient With Axial Spondyloarthritis and a History of aLeishmania donovaniInfection

López-Medina,

Doblas,

Escudero-Contreras

et al. 2023

J Rheumatol

View full text Add to dashboard Cite

show abstract

Immunosuppressants/secukinumab

2022

Reactions Weekly

View full text Add to dashboard Cite

Visceral Leishmaniasis after Anti-Interleukin 17A (IL-17A) Therapy in a Patient Affected by Psoriatic Arthritis

Cited by 4 publications

References 20 publications

CD4+ Th1 and Th17 responses and multifunctional CD8 T lymphocytes associated with cure or disease worsening in human visceral leishmaniasis

CD4+ Th1 and Th17 responses and multifunctional CD8 T lymphocytes associated with cure or disease worsening in human visceral leishmaniasis

Safe Treatment With Secukinumab in a Patient With Axial Spondyloarthritis and a History of aLeishmania donovaniInfection

Immunosuppressants/secukinumab

Contact Info

Product

Resources

About